Elvitegravir in treatment-experienced people
ثبت نشده
چکیده
Elvitegravir is an emerging integrase inhibitor. When elvitegravir is taken with a low dose of the drug ritonavir (Norvir), the concentration of elvitegravir in the blood rises and remains elevated for about a day. The manufacturer of elvitegravir, Gilead Sciences, is also developing another pharmacokinetic (PK) booster called cobicistat, which will be co-formulated with elvitegravir in the future.
منابع مشابه
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
BACKGROUND Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in patients in whom previous antiretroviral treatment failed. METHODS We conducted a randomised, double-blind, double-dummy, phase 3 study at 234 sites in 13 countries. Eligible patients had ...
متن کاملDolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is equivalent or superior to existing treatment regimens in both treatment-naïve and treatment-experienced patients including those with previous raltegravir or elvitegravir failure. The consistent efficacy coupled with excellent tolerabil...
متن کاملEmerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
Integrase is an essential HIV-1-specific enzyme that is an active target for antiretroviral drug development. Recently, a new class of drugs that specifically inhibits strand transfer, one of the three steps of HIV integration into the host DNA, has been developed. Two drugs in this class have reached late stages of development for use in HIV-1 infected individuals: raltegravir, which has just ...
متن کامل1568Use of the Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in a Predominantly African-American HIV Infected Population
Background. Elvitegravir (EVG) is an integrase strand transfer inhibitor (INSTI) based drug for the treatment of HIV-1 infection, co-formulated with cobicistat (COBI), a CYP3A4 inhibitor, emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF). The regimen consists of a single tablet, taken once daily. Two phase 3 clinical trials have established its efficacy and safety. Methods. A retrosp...
متن کاملHIV Treatment Bulletin (HTB) September/October 2009
s from the workshop, published in Reviews in Antiviral Therapy & Infectious Diseases 2011_3 are available to download from the meeting website. http://www.virology-education.com/index.cfm/t/Workshop_Materials/vid/34792068-01CF-4196-986A8271C014BBD7 Selected presentations are also available online. http://regist2.virology-education.com/2011/12HIV_PK/13_April.html Articles included in this issue ...
متن کامل